NasdaqGM - Nasdaq Real Time Price USD

Rhythm Pharmaceuticals, Inc. (RYTM)

Compare
55.24 -0.44 (-0.79%)
At close: December 13 at 4:00:01 PM EST
55.24 0.00 (0.00%)
After hours: December 13 at 4:20:00 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. David P. Meeker M.D. Chairman, President & CEO 1.35M -- 1954
Mr. Hunter C. Smith M.B.A. CFO & Treasurer 757.32k 1.88M 1969
Mr. Joseph Shulman Chief Technical Officer 677.27k 968.13k 1976
Mr. Yann Mazabraud Executive VP & Head of International 936.91k -- 1973
Ms. Jennifer Lee Executive VP & Head of North America 727.14k 779.08k 1975
Mr. Christopher German Corporate Controller, Principal Accounting Officer & Executive Director -- -- 1971
Dr. Alastair Garfield Ph.D. Chief Scientific Officer -- -- --
Mr. David Connolly Head of Investor Relations & Corporate Communications -- -- --
Mr. Jim Flaherty Senior VP & General Counsel -- -- --
Ms. Sarah Ryan Vice President of Sales & Marketing -- -- --

Rhythm Pharmaceuticals, Inc.

222 Berkeley Street
12th Floor
Boston, MA 02116
United States
857 264 4280 https://rhythmtx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
226

Description

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Corporate Governance

Rhythm Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 1, 2024 is 7. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 20, 2025 at 1:30 PM UTC - February 24, 2025 at 1:30 PM UTC

Rhythm Pharmaceuticals, Inc. Earnings Date

Recent Events

November 18, 2024 at 4:30 PM UTC

at Stifel Healthcare Conference

November 11, 2024 at 4:30 PM UTC

at Guggenheim Global Healthcare Conference

November 6, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

November 5, 2024 at 10:00 PM UTC

Q3 2024 Earnings Call

November 5, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 19, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 14, 2024 at 12:00 AM UTC

10-Q/A: Periodic Financial Reports

August 7, 2024 at 12:00 AM UTC

DEFA14A: Proxy Statements

August 6, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

June 17, 2024 at 12:00 AM UTC

DEFA14A: Proxy Statements

Related Tickers